Intended for healthcare professionals

News

Montelukast: UK regulator says asthma drug needs clearer warnings of side effects

BMJ 2024; 385 doi: https://doi.org/10.1136/bmj.q1048 (Published 08 May 2024) Cite this as: BMJ 2024;385:q1048
  1. Gareth Iacobucci
  1. The BMJ

The asthma drug montelukast (Singulair) will carry more prominent warnings in the UK to alert doctors and patients to its potentially serious behavioural and neuropsychiatric side effects.

Previously noted side effects associated with the oral treatment include sleep disturbances, depression, and agitation (which may affect up to one in 100 people); disturbances of attention or memory (up to one in 1000); and hallucinations and suicidal …

View Full Text

Log in

Log in through your institution

Subscribe

* For online subscription